It is worth mentioning that in our anti-IFN-γ antibodies-positive SLE cohort, two patients were treated with rituximab after the infection was controlled, and after multiple rituximab consolidation treatments, both two patients were subsequently stable, with no recurrent severe infections and no frequent lupus activity. The gene discussed is IFNG; the disease is systemic lupus erythematosus.